Akebia Therapeutics (AKBA) Total Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Liabilities data on file, last reported at $335.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $335.1 million, up 17.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $335.1 million (up 17.35% YoY), and the FY2025 annual result was $344.0 million, up 27.46% from the prior year.
• Total Liabilities retreated to $335.1 million in Q1 2026 per AKBA's latest filing, from $344.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $519.2 million in Q1 2022 and troughed at $252.7 million in Q1 2024.
• A 5-year average of $326.0 million and a median of $300.1 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities tumbled 42.21% in 2023, then grew 27.46% in 2025.
• A 5-year view of Total Liabilities shows it stood at $350.8 million in 2022, then decreased by 22.39% to $272.3 million in 2023, then retreated by 0.89% to $269.9 million in 2024, then climbed by 27.46% to $344.0 million in 2025, then declined by 2.56% to $335.1 million in 2026.
• Business Quant data shows AKBA's Total Liabilities at $335.1 million in Q1 2026, $344.0 million in Q4 2025, and $322.6 million in Q3 2025.